Marché mondial des médicaments contre l’insuffisance rénale terminale (IRT) – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des médicaments contre l'insuffisance rénale terminale (IRT)

Selon les rapports du CDC, on estime que plus de 37 millions de personnes aux États-Unis souffrent d'IRC, mais plus de 500 millions de personnes dans le monde sont touchées. On estime qu'un nombre croissant de patients souffrant d'insuffisance rénale stimule le marché. Il a également été constaté que les personnes souffrant d'IRT terminale et de diabète sont plus sensibles aux complications du COVID-19 que les personnes en bonne santé.

Data Bridge Market Research analyse le taux de croissance du marché des médicaments contre l'insuffisance rénale terminale (IRT) au cours de la période de prévision 2023-2030. Le TCAC attendu du marché des médicaments contre l'insuffisance rénale terminale (IRT) a tendance à être d'environ 13,4 % au cours de la période de prévision mentionnée. La valeur du marché est de 98,74 milliards USD en 2022 et elle atteindrait 270,01 milliards USD d'ici 2030. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché des médicaments contre l'insuffisance rénale terminale (IRT)

Market Definition

End-stage kidney disease drugs are used widely to treat end-stage kidney disease also known as the late stage renal disease, which occurs when chronic kidney disease reaches an advanced state. In this stage, the kidneys can no longer work, as they should to meet the body's needs. It damages the nephron and the kidney cannot function to remove the waste product from the body. The disease can cause other severe problems such as kidney failure, hypertension, brain aneurysm, and chronic pain.

End Stage Renal Disease (ESRD) Drug Market Dynamics

Drivers

• Increased Incidence of Kidney Disease

The growing incidence of chronic end stage renal disease (ESRD) drug worldwide is majorly responsible for increasing market growth. According to the National Kidney Foundation records, approximately 10% of the global population is affected by chronic end-stage renal disease (ESRD) drug (CKD). According to WHO 2019, around 1.13 billion people globally have hypertension. In 2014–2016, diabetes and hypertension were majorly responsible for about 75% of kidney failure. Thus, it boosts market growth.

• Rising Demand For Blood Tests

Out of all the major tests, the main test for the diagnosis of end stage renal disease (ESRD) drug includes a blood test that helps understand the kidneys' functionality. It measures levels of a waste product known as creatinine in the blood. Additionally, the demand for these tests is expected to increase as the occurrence of CKD is high and increasing in many parts of the world. The global incidence of end-stage renal disease (ESRD) is high and rising at a huge rate. Therefore, it creates more opportunities for the market growth.

Opportunities

• Technological Advancements

There have been several advances regarding the diagnostic and treatment procedures that are increasing the market growth. For instance, FMCNA established the National Intensive Renal Care Reserve in April 2020, which comprised devices that can deliver IHD, CRRT, and SLED/PIRRT. Such conditions that cause reduced kidney function can lead to chronic kidney diseae (CKD), which may develop over time and lead to end-stage renal end stage renal disease (ESRD) where the kidney can no longer function independently. The first human clinical trials of blood purification technologies for designing Wearable Artificial Kidney 2.0 was approved by the U.S. FDA in February 2014. This innovation aims to obtain satisfactory and effective results from kidney failure patients. Hence, all these advancemnets are boosting the market growth.

 Restraints/Challenges

• Side Effects of End stage renal disease (ESRD) Drugs

The major side effects that is related with these renal drugs could decrease the growth of the global renal drugs market during the forecast period. Effects such as fever, loss of appetite, and rashes, can hamper the market growth.

• High Cost of Treatment

The increased expenditure that is associated with these agents impedes the market growth. Treatments that include ACE inhibitors, diuretics, corticosteroids, and immunosuppressive therapy impede the growth of the market.

This end stage renal disease (ESRD) drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the end stage renal disease (ESRD) drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global End Stage Renal Disease (ESRD) Drug Market            

The increasing cases of COVID-19 directly associate with the growth of kidney-related diseases. For instance, according to the article in 2021, titled "Acute Kidney Injury in COVID-19: 90 Days of the Pandemic in a Brazilian Public Hospital," around 4–37% of COVID-19 cases involve the kidneys, and acute end stage renal disease (ESRD) drugs have an occurrence of 50% among hospitalized COVID-19 patients. Therefore, it has been found that the COVID-19 is having a high impact on the kidney health of patients, which in turn, is projected to increase the burden of kidney disorders and boost the market growth.

Recent Developments

• In 2022, the Health Minister launched a Hemodialysis unit at New Souillac in the presence of the World Health Representative to celebrate world kidney day in Mauritius. It comprises 22 hemodialysis machines that can accommodate about 150 patients and aims at further decentralizing the treatment of patients suffering from kidney disease.
• In 2021, Baxter launched the Sharesource Analytics 1.0 Digital Health Module to increase the clinical management of home dialysis patients.

Global End Stage Renal Disease (ESRD) Drug Market Scope

The end stage renal disease (ESRD) drug market is segmented on the basis of type, product type, indication, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Calcium Succinate
• Mk-3866
• Pacritinib
• Sanguinate
• Tesidolumab
• Others

Product Type

• Calcimimetics
• Vitamin D
• Sterols
• Potassium Binders
• Calcium-Based Phosphate Binders
• Others

Indication

• End Stage Renal Disease (ESRD) Induced Hyperparathyroidism
• End Stage Renal Disease (ESRD) Induced Hyperphosphatemia
• End Stage Renal Disease (ESRD) Induced Hyperkalaemia

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

End Stage Renal Disease (ESRD) Drug Market Regional Analysis/Insights

The end stage renal disease (ESRD) drug market is analyzed and market size insights and trends are provided by type, product type, indication, distribution channel and end-user as referenced above.

The major countries covered in the end stage renal disease (ESRD) drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Europe has been witnessing the highest growth for the end stage renal disease (ESRD) drug market throughout the forecasted period due to the strong presence of highly developing economies such as India and China along with the huge development of the healthcare infrastructure.

North America dominates the market because of the increase in the incidence of renal disease, mainly amongst the elderly population and the easy availability of advanced features.

La section par pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte lors de l'analyse prévisionnelle des données nationales.   

Analyse du paysage concurrentiel et des parts de marché mondiales des médicaments contre l'insuffisance rénale terminale (IRT)

Le paysage concurrentiel du marché des médicaments contre l'insuffisance rénale terminale (IRT) fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des médicaments contre l'insuffisance rénale terminale (IRT).

Les principaux acteurs opérant sur le marché des médicaments contre l’insuffisance rénale terminale (IRT) comprennent :

• Pfizer Inc (États-Unis)
• AstraZeneca (Royaume-Uni)
• Société Bristol-Myers Squibb (États-Unis)
• Dr. Reddy's Laboratories Ltd (Inde)
• Endo International plc (Irlande)
• Teva Pharmaceutical Industries Ltd (Israël)
• Sun Pharmaceutical Industries Ltd (Inde)
• Mylan NV (États-Unis)
• Novartis SA (Suisse)
• Lupin (Inde)
• Cipla Inc (Inde)
• Aurobindo Pharma (Inde)
• Fresenius SE & Co. KGaA (Allemagne)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japon)
• F. Hoffmann-La Roche SA (Suisse)
• Abbott (États-Unis)
• Kissei Pharmaceutical Co., Ltd (Japon)

SKU-44929